Belite Bio Inc ADR (BLTE NASDAQ) stock market data APIs
$73.2899
-4.96(-6.8%)
as of September 17, 2025
Try our APIs with
free plan!
Belite Bio Inc ADR Financial Data Overview
Price chart is built with
Anychart
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Prev. Close
73.2899
Open
68.3317
High
73.4747
Low
67.5352
52 wk Range
43.7-86.53
Market Cap
2 397 M
Shares Outstanding
32 833 K
EPS
-0.31
Beta
-1.504
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Belite Bio Inc ADR data using free add-ons & libraries
Get Belite Bio Inc ADR Fundamental Data
Belite Bio Inc ADR Fundamental data includes:
- Net Revenue:
- EBITDA: -25 499 500
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-11
- EPS/Forecast: -0.39
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Belite Bio Inc ADR News
New
Belite Bio (BLTE) Completes Phase 3 DRAGON Trial Enrollment For Stargardt Treatment
Belite Bio recently announced the successful completion of the Phase 3 DRAGON clinical trial, which significantly focuses on treating Stargardt disease type 1. The company's share price increased by 1...
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation...
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
Belite Bio, Inc Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer...
Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal Point Capital$125 million financing upfront with u...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
